From Wikipedia, the free encyclopedia
Induced stem cells (
iSC) are
stem cells derived from
somatic,
reproductive,
pluripotent or other cell types by deliberate
epigenetic reprogramming. They are classified as either
totipotent (iTC),
pluripotent (iPSC) or
progenitor (multipotent – iMSC, also called an induced multipotent progenitor cell – iMPC) or
unipotent – (iUSC) according to their
developmental potential and degree of dedifferentiation. Progenitors are obtained by so-called
direct reprogramming or directed
differentiation and are also called induced
somatic stem cells.
Three techniques are widely recognized:
- Transplantation of nuclei taken from somatic cells into an oocyte (egg cell) lacking its own nucleus (removed in lab)
- Fusion of somatic cells with pluripotent stem cells and
- Transformation of somatic cells into stem cells, using the genetic material encoding reprogramming protein factors, recombinant proteins; microRNA, a synthetic, self-replicating polycistronic RNA[16] and low-molecular weight biologically active substances.
Natural processes
In 1895
Thomas Morgan removed one of a
frog's two
blastomeres and found that
amphibians are able to form whole
embryos
from the remaining part. This meant that the cells can change their
differentiation pathway. In 1924 Spemann and Mangold demonstrated the
key importance of cell–cell inductions during animal development. The reversible transformation of cells of one differentiated cell type to another is called
metaplasia. This transition can be a part of the normal maturation process, or caused by an inducement.
One example is the transformation of
iris cells to
lens cells in the process of maturation and transformation of
retinal pigment epithelium cells into the neural retina during regeneration in adult
newt eyes. This process allows the body to replace cells not suitable to new conditions with more suitable new cells. In
Drosophila
imaginal discs, cells have to choose from a limited number of standard
discrete differentiation states. The fact that transdetermination
(change of the path of differentiation) often occurs for a group of
cells rather than single cells shows that it is induced rather than part
of maturation.
Some types of mature, specialized adult cells can naturally
revert to stem cells. For example, "chief" cells express the stem cell
marker Troy. While they normally produce digestive fluids for the
stomach, they can revert into stem cells to make temporary repairs to
stomach injuries, such as a cut or damage from infection. Moreover, they
can make this transition even in the absence of noticeable injuries and
are capable of replenishing entire gastric units, in essence serving as
quiescent "reserve" stem cells. Differentiated airway epithelial cells can revert into stable and functional stem cells
in vivo.
After injury, mature terminally differentiated kidney cells
dedifferentiate into more primordial versions of themselves and then
differentiate into the cell types needing replacement in the damaged
tissue Macrophages can self-renew by local proliferation of mature differentiated cells.
In newts, muscle tissue is regenerated from specialized muscle cells
that dedifferentiate and forget the type of cell they had been. This
capacity to regenerate does not decline with age and may be linked to
their ability to make new stem cells from muscle cells on demand.
A variety of nontumorigenic stem cells display the ability to
generate multiple cell types. For instance, multilineage-differentiating
stress-enduring
(Muse)
cells are stress-tolerant adult human stem cells that can self-renew.
They form characteristic cell clusters in suspension culture that
express a set of genes associated with pluripotency and can
differentiate into
endodermal, ectodermal and mesodermal cells both in vitro and in vivo.
Other well-documented examples of
transdifferentiation and their significance in development and regeneration were described in detail.
Induced totipotent cells
SCNT-mediated
Induced totipotent cells can be obtained by reprogramming somatic cells with
somatic-cell nuclear transfer
(SCNT). The process involves sucking out the nucleus of a somatic
(body) cell and injecting it into an oocyte that has had its nucleus
removed.
Using an approach based on the protocol outlined by Tachibana et al.,
hESCs can be generated by SCNT using dermal fibroblasts nuclei from
both a middle-aged 35-year-old male and an elderly, 75-year-old male,
suggesting that age-associated changes are not necessarily an impediment
to SCNT-based nuclear reprogramming of human cells. Such reprogramming of somatic cells to a pluripotent state holds huge potentials for
regenerative medicine. Unfortunately, the cells generated by this technology, potentially are not completely protected from the
immune system of the patient (donor of nuclei), because they have the same
mitochondrial DNA, as a donor of oocytes, instead of the patients mitochondrial DNA. This reduces their value as a source for
autologous stem cell transplantation therapy, as for the present, it is not clear whether it can induce an immune response of the patient upon treatment.
Induced androgenetic haploid embryonic stem cells can be used
instead of sperm for cloning. These cells, synchronized in M phase and
injected into the oocyte can produce viable offspring.
These developments, together with data on the possibility of unlimited oocytes from mitotically active reproductive stem cells,
offer the possibility of industrial production of transgenic farm
animals. Repeated recloning of viable mice through a SCNT method that
includes a
histone deacetylase inhibitor, trichostatin, added to the cell culture medium, show that it may be possible to reclone animals indefinitely with no visible accumulation of reprogramming or genomic errors However, research into technologies to develop sperm and egg cells from stem cells raises
bioethical issues.
Such technologies may also have far-reaching clinical applications for overcoming cytoplasmic defects in human oocytes. For example, the technology could prevent inherited
mitochondrial disease
from passing to future generations. Mitochondrial genetic material is
passed from mother to child. Mutations can cause diabetes, deafness, eye
disorders, gastrointestinal disorders, heart disease, dementia and
other neurological diseases. The nucleus from one human egg has been
transferred to another, including its mitochondria, creating a cell that
could be regarded as having two mothers. The eggs were then fertilised
and the resulting embryonic stem cells carried the swapped mitochondrial
DNA.
As evidence that the technique is safe author of this method points to
the existence of the healthy monkeys that are now more than four years
old – and are the product of mitochondrial transplants across different
genetic backgrounds.
In late-generation
telomerase-deficient
(Terc−/−) mice, SCNT-mediated reprogramming mitigates telomere
dysfunction and mitochondrial defects to a greater extent than
iPSC-based reprogramming.
Other cloning and totipotent transformation achievements have been described.
Obtained without SCNT
Recently
some researchers succeeded to get the totipotent cells without the aid
of SCNT. Totipotent cells were obtained using the epigenetic factors
such as oocyte germinal isoform of histone.
Reprogramming in vivo, by transitory induction of the four factors Oct4,
Sox2, Klf4 and c-Myc in mice, confers totipotency features.
Intraperitoneal injection of such in vivo iPS cells generates
embryo-like structures that express embryonic and extraembryonic (
trophectodermal) markers.
The developmental potential of mouse pluripotent stem cells to yield
both embryonic and extra-embryonic lineages also can be expanded by
microRNA
miR-34a deficiency leading to strong induction of endogenous
retroviruses MuERV-L (MERVL).
Rejuvenation to iPSCs
Transplantation of pluripotent/embryonic stem cells into the body of adult mammals, usually leads to the formation of teratomas,
which can then turn into a malignant tumor teratocarcinoma. However,
putting teratocarcinoma cells into the embryo at the blastocyst stage,
caused them to become incorporated in the cell mass and often produced a
normal healthy chimeric (i.e. composed of cells from different
organisms) animal
iPSc were first obtained in the form of transplantable
teratocarcinoma induced by grafts taken from mouse embryos. Teratocarcinoma formed from somatic cells.
Genetically mosaic mice were obtained from malignant teratocarcinoma cells, confirming the cells' pluripotency. It turned out that teratocarcinoma cells are able to maintain a culture of pluripotent
embryonic stem cell in an undifferentiated state, by supplying the culture medium with various factors.
In the 1980s, it became clear that transplanting pluripotent/embryonic
stem cells into the body of adult mammals, usually leads to the
formation of
teratomas, which can then turn into a malignant tumor teratocarcinoma. However, putting teratocarcinoma cells into the embryo at the blastocyst stage, caused them to become incorporated in the
inner cell mass and often produced a normal chimeric (i.e. composed of cells from different organisms) animal.
This indicated that the cause of the teratoma is a dissonance - mutual
miscommunication between young donor cells and surrounding adult cells
(the recipient's so-called "
niche").
In August 2006, Japanese researchers circumvented the need for an oocyte, as in SCNT. By reprograming mouse embryonic
fibroblasts into pluripotent stem cells via the ectopic expression of four
transcription factors, namely
Oct4,
Sox2,
Klf4 and
c-Myc,
they proved that the overexpression of a small number of factors can
push the cell to transition to a new stable state that is associated
with changes in the activity of thousands of genes.
Human
somatic cells are made pluripotent by transducing them with factors
that induces pluripotency (OCT 3/4, SOX2, Klf4, c-Myc, NANOG and LIN28).
This results in the production of IPS cells, which can differentiate
into any cells of the three embryonic germ layers (Mesoderm, Endoderm,
Ectoderm).
Reprogramming mechanisms are thus linked, rather than independent and are centered on a small number of genes.
IPSC properties are very similar to ESCs. iPSCs have been shown to support the development of all-iPSC mice using a
tetraploid (4n) embryo,
the most stringent assay for developmental potential. However, some
genetically normal iPSCs failed to produce all-iPSC mice because of
aberrant epigenetic silencing of the imprinted
Dlk1-Dio3 gene cluster.
An important advantage of iPSC over ESC is that they can be
derived from adult cells, rather than from embryos. Therefore, it became
possible to obtain iPSC from adult and even elderly patients.
Reprogramming somatic cells to iPSC leads to rejuvenation. It was
found that reprogramming leads to telomere lengthening and subsequent
shortening after their differentiation back into fibroblast-like
derivatives. Thus, reprogramming leads to the restoration of embryonic telomere length, and hence increases the potential number of cell divisions otherwise limited by the
Hayflick limit.
However, because of the dissonance between rejuvenated cells and
the surrounding niche of the recipient's older cells, the injection of
his own iPSC usually leads to an
immune response, which can be used for medical purposes, or the formation of tumors such as teratoma.
The reason has been hypothesized to be that some cells differentiated
from ESC and iPSC in vivo continue to synthesize embryonic
protein isoforms. So, the immune system might detect and attack cells that are not cooperating properly.
A small molecule called MitoBloCK-6 can force the pluripotent stem cells to die by triggering
apoptosis (via
cytochrome c release across the
mitochondrial
outer membrane) in human pluripotent stem cells, but not in
differentiated cells. Shortly after differentiation, daughter cells
became resistant to death. When MitoBloCK-6 was introduced to
differentiated cell lines, the cells remained healthy. The key to their
survival, was hypothesized to be due to the changes undergone by
pluripotent stem cell mitochondria in the process of cell
differentiation. This ability of MitoBloCK-6 to separate the pluripotent
and differentiated cell lines has the potential to reduce the risk of
teratomas and other problems in regenerative medicine.
In 2012 other
small molecules
(selective cytotoxic inhibitors of human pluripotent stem cells –
hPSCs) were identified that prevented human pluripotent stem cells from
forming teratomas in mice. The most potent and selective compound of
them (PluriSIn #1) inhibits
stearoyl-coA desaturase (the key enzyme in
oleic acid
biosynthesis), which finally results in apoptosis. With the help of
this molecule the undifferentiated cells can be selectively removed from
culture.
An efficient strategy to selectively eliminate pluripotent cells with
teratoma potential is targeting pluripotent stem cell-specific
antiapoptotic factor(s) (i.e.,
survivin or Bcl10). A single treatment with chemical survivin inhibitors (e.g.,
quercetin
or YM155) can induce selective and complete cell death of
undifferentiated hPSCs and is claimed to be sufficient to prevent
teratoma formation after transplantation. However, it is unlikely that any kind of preliminary clearance,
is able to secure the replanting iPSC or ESC. After the selective
removal of pluripotent cells, they re-emerge quickly by reverting
differentiated cells into stem cells, which leads to tumors. This may be due to the disorder of
let-7 regulation of its target Nr6a1 (also known as
Germ cell nuclear factor
- GCNF), an embryonic transcriptional repressor of pluripotency genes
that regulates gene expression in adult fibroblasts following
micro-RNA miRNA loss.
Teratoma formation by pluripotent stem cells may be caused by low activity of
PTEN enzyme,
reported to promote the survival of a small population (0.1–5% of total
population) of highly tumorigenic, aggressive, teratoma-initiating
embryonic-like carcinoma cells during differentiation. The survival of
these teratoma-initiating cells is associated with failed repression of
Nanog as well as a propensity for increased glucose and cholesterol metabolism. These teratoma-initiating cells also expressed a lower ratio of p53/p21 when compared to non-tumorigenic cells.
In connection with the above safety problems, the use iPSC for cell therapy is still limited. However, they can be used for a variety of other purposes - including the modeling of disease, screening (selective selection) of drugs, toxicity testing of various drugs.
Small molecule modulators of stem-cell fate.
The tissue grown from iPSCs, placed in the "chimeric" embryos in the
early stages of mouse development, practically do not cause an immune
response (after the embryos have grown into adult mice) and are suitable
for
autologous transplantation
At the same time, full reprogramming of adult cells in vivo within
tissues by transitory induction of the four factors Oct4, Sox2, Klf4 and
c-Myc in mice results in teratomas emerging from multiple organs.
Furthermore, partial reprogramming of cells toward pluripotency in vivo
in mice demonstrates that incomplete reprogramming entails epigenetic
changes (failed repression of
Polycomb targets and altered
DNA methylation) in cells that drive cancer development.
Chemical inducement
By using solely
small molecules,
Deng Hongkui and colleagues demonstrated that endogenous "master genes"
are enough for cell fate reprogramming. They induced a pluripotent
state in adult cells from mice using seven small-molecule compounds.
The effectiveness of the method is quite high: it was able to convert
0.02% of the adult tissue cells into iPSCs, which is comparable to the
gene insertion conversion rate.
The authors note that the mice generated from CiPSCs were "100% viable
and apparently healthy for up to 6 months". So, this chemical
reprogramming strategy has potential use in generating functional
desirable cell types for clinical applications.
In 2015 a robust chemical reprogramming system was established
with a yield up to 1,000-fold greater than that of the previously
reported protocol. So, chemical reprogramming became a promising
approach to manipulate cell fates.
Differentiation from induced teratoma
The
fact that human iPSCs capable of forming teratomas not only in humans
but also in some animal body, in particular in mice or pigs, allowed to
develop a method for differentiation of iPSCs in vivo. For this purpose,
iPSCs with an agent for inducing differentiation into target cells are
injected to
genetically modified pig or mouse that has suppressed immune system activation on human cells.
The formed teratoma is cut out and used for the isolation of the necessary differentiated human cells by means of
monoclonal antibody
to tissue-specific markers on the surface of these cells. This method
has been successfully used for the production of functional myeloid,
erythroid and lymphoid human cells suitable for transplantation (yet
only to mice).
Mice engrafted with human iPSC teratoma-derived hematopoietic cells
produced human B and T cells capable of functional immune responses.
These results offer hope that in vivo generation of patient customized
cells is feasible, providing materials that could be useful for
transplantation, human antibody generation and drug screening
applications.
Using MitoBloCK-6
and/or PluriSIn # 1 the differentiated progenitor cells can be further
purified from teratoma forming pluripotent cells. The fact, that the
differentiation takes place even in the teratoma niche, offers hope that
the resulting cells are sufficiently stable to stimuli able to cause
their transition back to the dedifferentiated (pluripotent) state and
therefore safe. A similar in vivo differentiation system, yielding
engraftable hematopoietic stem cells from mouse and human iPSCs in
teratoma-bearing animals in combination with a maneuver to facilitate
hematopoiesis, was described by Suzuki et al.
They noted that neither leukemia nor tumors were observed in recipients
after intravenous injection of iPSC-derived hematopoietic stem cells
into irradiated recipients. Moreover, this injection resulted in
multilineage and long-term reconstitution of the hematolymphopoietic
system in serial transfers. Such system provides a useful tool for
practical application of iPSCs in the treatment of hematologic and
immunologic diseases.
For further development of this method animal in which is grown
the human cell graft, for example mouse, must have so modified genome
that all its cells express and have on its surface human
SIRPα.
To prevent rejection after transplantation to the patient of the
allogenic organ or tissue, grown from the pluripotent stem cells in vivo
in the animal, these cells should express two molecules:
CTLA4-Ig, which disrupts T cell costimulatory pathways and
PD-L1, which activates T cell inhibitory pathway.
Differentiated cell types
Retinal cells
In
the near-future, clinical trials designed to demonstrate the safety of
the use of iPSCs for cell therapy of the people with age-related macular
degeneration, a disease causing blindness through retina damaging, will
begin. There are several articles describing methods for producing
retinal cells from iPSCs
and how to use them for cell therapy. Reports of iPSC-derived retinal pigmented epithelium transplantation showed enhanced
visual-guided behaviors of experimental animals for 6 weeks after transplantation.
However, clinical trials have been successful: ten patients suffering
from retinitis pigmentosa have had their eyesight restored – including a
woman who had only 17 percent of her vision left.
Lung and airway epithelial cells
Chronic lung diseases such as idiopathic pulmonary fibrosis and cystic fibrosis or
chronic obstructive pulmonary disease and
asthma
are leading causes of morbidity and mortality worldwide with a
considerable human, societal and financial burden. So there is an urgent
need for effective cell therapy and
lung tissue engineering.
Several protocols have been developed for generation of the most cell types of the
respiratory system, which may be useful for deriving patient-specific therapeutic cells.
Reproductive cells
Some
lines of iPSCs have the potentiality to differentiate into male germ
cells and oocyte-like cells in an appropriate niche (by culturing in
retinoic acid and porcine follicular fluid differentiation medium or
seminiferous tubule transplantation). Moreover, iPSC transplantation
make a contribution to repairing the testis of infertile mice,
demonstrating the potentiality of gamete derivation from iPSCs in vivo
and in vitro.
Induced progenitor stem cells
Direct transdifferentiation
The
risk of cancer and tumors creates the need to develop methods for safer
cell lines suitable for clinical use. An alternative approach is
so-called "direct reprogramming" – transdifferentiation of cells without
passing through the pluripotent state. The basis for this approach was that
5-azacytidine – a DNA demethylation reagent – can cause the formation of
myogenic, chondrogenic and adipogeni clones in the immortal cell line of mouse embryonic fibroblasts and that the activation of a single gene, later named MyoD1, is sufficient for such reprogramming.
Compared with iPSC whose reprogramming requires at least two weeks, the
formation of induced progenitor cells sometimes occurs within a few
days and the efficiency of reprogramming is usually many times higher.
This reprogramming does not always require cell division. The cells resulting from such reprogramming are more suitable for cell therapy because they do not form teratomas.
For example, Chandrakanthan et al., & Pimanda describe the
generation of tissue-regenerative multipotent stem cells (iMS cells) by
treating mature bone and fat cells transiently with a growth factor (
platelet-derived growth factor–AB
(PDGF-AB)) and 5-Azacytidine. These authors claim that: "Unlike primary
mesenchymal stem cells, which are used with little objective evidence
in clinical practice to promote tissue repair, iMS cells contribute
directly to in vivo tissue regeneration in a context-dependent manner
without forming tumors" and so "has significant scope for application in
tissue regeneration."
Single transcription factor transdifferentiation
Originally
only early embryonic cells could be coaxed into changing their
identity. Mature cells are resistant to changing their identity once
they've committed to a specific kind. However, brief expression of a
single transcription factor, the ELT-7 GATA factor, can convert the
identity of fully differentiated, specialized non-endodermal cells of
the
pharynx into fully differentiated intestinal cells in intact
larvae and adult roundworm
Caenorhabditis elegans with no requirement for a dedifferentiated intermediate.
Transdifferentiation with CRISPR-mediated activator
The cell fate can be effectively manipulated by
epigenome editing. In particular, by directly activating of specific endogenous gene expression with
CRISPR-mediated activator. When
dCas9
(that has been modified so that it no longer cuts DNA, but still can be
guided to specific sequences and to bind to them) is combined with
transcription activators, it can precisely manipulate endogenous gene
expression. Using this method, Wei et al., enhanced the expression of
endogenous
Cdx2 and
Gata6
genes by CRISPR-mediated activators, thus directly converted mouse
embryonic stem cells into two extraembryonic lineages, i.e., typical
trophoblast stem cells and extraembryonic endoderm cells.
An analogous approach was used to induce activation of the endogenous
Brn2, Ascl1, and Myt1l genes to convert mouse embryonic fibroblasts to
induced neuronal cells.
Thus, transcriptional activation and epigenetic remodeling of
endogenous master transcription factors are sufficient for conversion
between cell types. The rapid and sustained activation of endogenous
genes in their native chromatin context by this approach may facilitate
reprogramming with transient methods that avoid genomic integration and
provides a new strategy for overcoming epigenetic barriers to cell fate
specification.
Phased process modeling regeneration
Another way of reprogramming is the simulation of the processes that occur during
amphibian limb regeneration. In
urodele
amphibians, an early step in limb regeneration is skeletal muscle fiber
dedifferentiation into a cellulate that proliferates into limb tissue.
However, sequential small molecule treatment of the muscle fiber with
myoseverin,
reversine (the
aurora B kinase inhibitor) and some other chemicals: BIO (glycogen synthase-3 kinase inhibitor),
lysophosphatidic acid (pleiotropic activator of G-protein-coupled receptors),
SB203580 (
p38 MAP kinase inhibitor), or
SQ22536
(adenylyl cyclase inhibitor) causes the formation of new muscle cell
types as well as other cell types such as precursors to fat, bone and
nervous system cells.
Antibody-based transdifferentiation
The researchers discovered that
GCSF-mimicking
antibody can activate a growth-stimulating receptor on
marrow
cells in a way that induces marrow stem cells that normally develop
into white blood cells to become neural progenitor cells. The technique enables researchers to search large libraries of antibodies and quickly select the ones with a desired biological effect.
Reprograming by bacteria
The
human gastrointestinal tract is colonized by a vast community of
symbionts and commensals. The researchers demonstrate the phenomenon of
somatic cell reprograming by bacteria and generation of multipotential
cells from adult human dermal fibroblast cells by incorporating Lactic
acid bacteria
This cellular transdifferentiation is caused by ribosomes and "can
occur via donor bacteria that are swallowed and digested by host cells,
which may induce ribosomal stress and stimulate cellular developmental
plasticity."
Conditionally reprogrammed cells
Schlegel and Liu demonstrated that the combination of feeder cells and a
Rho kinase inhibitor (Y-27632) induces normal and tumor epithelial cells from many tissues to
proliferate indefinitely in vitro. This process occurs without the need
for transduction of exogenous viral or cellular genes. These cells have
been termed "Conditionally Reprogrammed Cells (CRC)". The induction of
CRCs is rapid and results from reprogramming of the entire cell
population. CRCs do not express high levels of proteins characteristic
of iPSCs or embryonic stem cells (ESCs) (e.g., Sox2, Oct4, Nanog, or
Klf4). This induction of CRCs is reversible and removal of Y-27632 and
feeders allows the cells to differentiate normally. CRC technology can generate 2
×10
6
cells in 5 to 6 days from needle biopsies and can generate cultures
from cryopreserved tissue and from fewer than four viable cells. CRCs
retain a normal
karyotype and remain nontumorigenic. This technique also efficiently establishes cell cultures from human and rodent tumors.
The ability to rapidly generate many tumor cells from small
biopsy specimens and frozen tissue provides significant opportunities
for cell-based diagnostics and therapeutics (including chemosensitivity
testing) and greatly expands the value of biobanking. Using CRC technology, researchers were able to identify an effective therapy for a patient with a rare type of lung tumor. Engleman's group
describes a pharmacogenomic platform that facilitates rapid discovery
of drug combinations that can overcome resistance using CRC system. In
addition, the CRC method allows for the genetic manipulation of
epithelial cells ex vivo and their subsequent evaluation in vivo in the
same host. While initial studies revealed that co-culturing epithelial
cells with Swiss 3T3 cells J2 was essential for CRC induction, with
transwell culture plates, physical contact between feeders and
epithelial cells is not required for inducing CRCs and more importantly
that irradiation of the feeder cells is required for this induction.
Consistent with the transwell experiments, conditioned medium induces
and maintains CRCs, which is accompanied by a concomitant increase of
cellular telomerase activity. The activity of the conditioned medium
correlates directly with radiation-induced feeder cell apoptosis. Thus,
conditional reprogramming of epithelial cells is mediated by a
combination of Y-27632 and a soluble factor(s) released by apoptotic
feeder cells.
Riegel et al.
demonstrate that mouse ME cells isolated from normal mammary glands or
from mouse mammary tumor virus (MMTV)-Neu–induced mammary tumors, can be
cultured indefinitely as conditionally reprogrammed cells (CRCs). Cell
surface progenitor-associated markers are rapidly induced in normal
mouse ME-CRCs relative to ME cells. However, the expression of certain
mammary progenitor subpopulations, such as CD49f+ ESA+ CD44+, drops
significantly in later passages. Nevertheless, mouse ME-CRCs grown in a
three-dimensional extracellular matrix gave rise to mammary acinar
structures. ME-CRCs isolated from MMTV-Neu transgenic mouse mammary
tumors express high levels of HER2/neu, as well as tumor-initiating cell
markers, such as CD44+, CD49f+ and ESA+ (EpCam). These patterns of
expression are sustained in later CRC passages. Early and late passage
ME-CRCs from MMTV-Neu tumors that were implanted in the mammary fat pads
of syngeneic or nude mice developed vascular tumors that metastasized
within 6 weeks of transplantation. Importantly, the histopathology of
these tumors was indistinguishable from that of the parental tumors that
develop in the MMTV-Neu mice. Application of the CRC system to mouse
mammary epithelial cells provides an attractive model system to study
the genetics and phenotype of normal and transformed mouse epithelium in
a defined culture environment and in vivo transplant studies.
A different approach to CRC is to inhibit
CD47 – a
membrane protein that is the
thrombospondin-1 receptor. Loss of CD47 permits sustained proliferation of primary
murine endothelial cells, increases asymmetric division and enables these cells to spontaneously reprogram to form multipotent
embryoid body-like clusters. CD47 knockdown acutely increases
mRNA
levels of c-Myc and other stem cell transcription factors in cells in
vitro and in vivo. Thrombospondin-1 is a key environmental signal that
inhibits stem cell self-renewal via CD47. Thus, CD47 antagonists enable
cell self-renewal and reprogramming by overcoming negative regulation of
c-Myc and other stem cell transcription factors. In vivo blockade of CD47 using an antisense
morpholino
increases survival of mice exposed to lethal total body irradiation due
to increased proliferative capacity of bone marrow-derived cells and
radioprotection of radiosensitive gastrointestinal tissues.
Lineage-specific enhancers
Differentiated
macrophages can self-renew in tissues and expand long-term in culture. Under certain conditions macrophages can divide without losing features they have acquired while specializing into
immune cells – which is usually not possible with
differentiated cells. The macrophages achieve this by activating a
gene network similar to one found in embryonic stem cells.
Single-cell analysis revealed that,
in vivo,
proliferating macrophages can derepress a macrophage-specific enhancer
repertoire associated with a gene network controlling self-renewal. This
happened when concentrations of two transcription factors named
MafB and
c-Maf
were naturally low or were inhibited for a short time. Genetic
manipulations that turned off MafB and c-Maf in the macrophages caused
the cells to start a self-renewal program. The similar network also
controls embryonic stem cell self-renewal but is associated with
distinct embryonic stem cell-specific enhancers.
Hence macrophages isolated from MafB- and c-Maf-double deficient mice divide indefinitely; the self-renewal depends on
c-Myc and
Klf4.
Indirect lineage conversion
Indirect
lineage conversion is a reprogramming methodology in which somatic
cells transition through a plastic intermediate state of partially
reprogrammed cells (pre-iPSC), induced by brief exposure to
reprogramming factors, followed by differentiation in a specially
developed chemical environment (artificial niche).
This method could be both more efficient and safer, since it does
not seem to produce tumors or other undesirable genetic changes and
results in much greater yield than other methods. However, the safety of
these cells remains questionable. Since lineage conversion from
pre-iPSC relies on the use of iPSC reprogramming conditions, a fraction
of the cells could acquire pluripotent properties if they do not stop
the de-differentation process in vitro or due to further
de-differentiation in vivo.
Outer membrane glycoprotein
A common feature of pluripotent stem cells is the specific nature of protein
glycosylation of their outer membrane. That distinguishes them from most nonpluripotent cells, although not
white blood cells. The
glycans
on the stem cell surface respond rapidly to alterations in cellular
state and signaling and are therefore ideal for identifying even minor
changes in cell populations. Many
stem cell markers are based on cell surface glycan epitopes including the widely used markers
SSEA-3, SSEA-4, Tra 1-60 and Tra 1-81. Suila Heli et al.
speculate that in human stem cells extracellular O-GlcNAc and
extracellular O-LacNAc, play a crucial role in the fine tuning of
Notch signaling pathway
- a highly conserved cell signaling system, that regulates cell fate
specification, differentiation, left–right asymmetry, apoptosis,
somitogenesis, angiogenesis and plays a key role in stem cell
proliferation (reviewed by Perdigoto and Bardin and Jafar-Nejad et al.)
Changes in outer membrane protein glycosylation are markers of
cell states connected in some way with pluripotency and differentiation.
The glycosylation change is apparently not just the result of the
initialization of gene expression, but perform as an important gene
regulator involved in the acquisition and maintenance of the
undifferentiated state.
For example, activation of
glycoprotein ACA,
linking glycosylphosphatidylinositol on the surface of the progenitor
cells in human peripheral blood, induces increased expression of genes
Wnt,
Notch-1,
BMI1 and
HOXB4 through a signaling cascade
PI3K/
Akt/
mTor/
PTEN and promotes the formation of a self-renewing population of hematopoietic stem cells.
Furthermore, dedifferentiation of progenitor cells induced by
ACA-dependent signaling pathway leads to ACA-induced pluripotent stem
cells, capable of differentiating in vitro into cells of all three
germ layers.
[164]
The study of
lectins' ability to maintain a culture of pluripotent human stem cells has led to the discovery of lectin
Erythrina crista-galli (ECA), which can serve as a simple and highly effective matrix for the cultivation of human pluripotent stem cells.
Reprogramming through a physical approach
Cell adhesion protein E-cadherin is indispensable for a robust pluripotent
phenotype. During reprogramming for iPS cell generation,
N-cadherin can replace function of E-cadherin.
These functions of cadherins are not directly related to adhesion
because sphere morphology helps maintaining the "stemness" of stem
cells.
Moreover, sphere formation, due to forced growth of cells on a low
attachment surface, sometimes induces reprogramming. For example, neural
progenitor cells can be generated from fibroblasts directly through a
physical approach without introducing exogenous reprogramming factors.
Physical cues, in the form of parallel microgrooves on the
surface of cell-adhesive substrates, can replace the effects of
small-molecule epigenetic modifiers and significantly improve
reprogramming efficiency. The mechanism relies on the mechanomodulation
of the cells' epigenetic state. Specifically, "decreased histone
deacetylase activity and upregulation of the expression of WD repeat
domain 5 (WDR5) – a subunit of H3 methyltranferase – by microgrooved
surfaces lead to increased histone H3 acetylation and methylation".
Nanofibrous scaffolds with aligned fibre orientation produce effects
similar to those produced by microgrooves, suggesting that changes in
cell morphology may be responsible for modulation of the epigenetic
state.
Substrate rigidity is an important biophysical cue influencing neural
induction and subtype specification. For example, soft substrates
promote neuroepithelial conversion while inhibiting
neural crest differentiation of hESCs in a
BMP4-dependent manner. Mechanistic studies revealed a multi-targeted mechanotransductive process involving mechanosensitive
Smad phosphorylation and nucleocytoplasmic shuttling, regulated by rigidity-dependent
Hippo/
YAP activities and
actomyosin cytoskeleton integrity and
contractility.
Mouse embryonic stem cells (mESCs) undergo self-renewal in the presence of the
cytokine leukemia inhibitory factor (LIF). Following LIF withdrawal, mESCs differentiate, accompanied by an increase in cell–substratum
adhesion
and cell spreading. Restricted cell spreading in the absence of LIF by
either culturing mESCs on chemically defined, weakly adhesive
biosubstrates, or by manipulating the
cytoskeleton
allowed the cells to remain in an undifferentiated and pluripotent
state. The effect of restricted cell spreading on mESC self-renewal is
not mediated by increased intercellular adhesion, as inhibition of mESC
adhesion using a function blocking anti E-cadherin antibody or
siRNA does not promote differentiation.
Possible mechanisms of stem cell fate predetermination by physical
interactions with the extracellular matrix have been described.
A new method has been developed that turns cells into stem cells
faster and more efficiently by 'squeezing' them using 3D
microenvironment stiffness and density of the surrounding gel. The
technique can be applied to a large number of cells to produce stem
cells for medical purposes on an industrial scale.
Cells involved in the reprogramming process change
morphologically as the process proceeds. This results in physical
difference in adhesive forces among cells. Substantial differences in
'adhesive signature' between pluripotent stem cells, partially
reprogrammed cells, differentiated progeny and somatic cells allowed to
develop separation process for isolation of pluripotent stem cells in
microfluidic devices, which is:
- fast (separation takes less than 10 minutes);
- efficient (separation results in a greater than 95 percent pure iPS cell culture);
- innocuous (cell survival rate is greater than 80 percent and the
resulting cells retain normal transcriptional profiles, differentiation
potential and karyotype).
Stem cells possess mechanical memory (they remember past physical signals) – with the
Hippo signaling pathway factors: Yes-associated protein (YAP) and
transcriptional coactivator
with PDZ-binding domain (TAZ) acting as an intracellular mechanical
rheostat—that stores information from past physical environments and
influences the cells' fate.
Neural stem cells
Stroke
and many neurodegenerative disorders such as Parkinson's disease,
Alzheimer's disease, amyotrophic lateral sclerosis need cell replacement
therapy. The successful use of converted neural cells (cNs) in
transplantations open a new avenue to treat such diseases.
Nevertheless, induced neurons (iNs), directly converted from
fibroblasts are terminally committed and exhibit very limited
proliferative ability that may not provide enough
autologous donor cells for transplantation.
Self-renewing induced neural stem cells (iNSCs) provide additional
advantages over iNs for both basic research and clinical applications.
For example, under specific growth conditions, mouse fibroblasts
can be reprogrammed with a single factor, Sox2, to form iNSCs that
self-renew in culture and after transplantation can survive and
integrate without forming tumors in mouse brains.
INSCs can be derived from adult human fibroblasts by non-viral
techniques, thus offering a safe method for autologous transplantation
or for the development of cell-based disease models.
Neural chemically induced progenitor cells (ciNPCs) can be
generated from mouse tail-tip fibroblasts and human urinary somatic
cells without introducing exogenous factors, but - by a chemical
cocktail, namely VCR (V,
VPA, an
inhibitor of HDACs; C, CHIR99021, an
inhibitor of GSK-3 kinases and R,
RepSox, an inhibitor of
TGF beta signaling pathways), under a physiological
hypoxic condition. Alternative cocktails with inhibitors of histone deacetylation, glycogen synthase kinase and TGF-β pathways (where:
sodium butyrate (NaB) or
Trichostatin A (TSA) could replace VPA,
Lithium chloride (LiCl) or lithium carbonate (Li2CO3) could substitute CHIR99021, or Repsox may be replaced with
SB-431542 or
Tranilast) show similar efficacies for ciNPC induction.
Zhang, et al.,
[186]
also report highly efficient reprogramming of mouse fibroblasts into
induced neural stem cell-like cells (ciNSLCs) using a cocktail of nine
components.
Multiple methods of direct transformation of somatic cells into induced neural stem cells have been described.
Proof of principle experiments demonstrate that it is possible to convert transplanted human fibroblasts and human
astrocytes
directly in the brain that are engineered to express inducible forms of
neural reprogramming genes, into neurons, when reprogramming genes (
Ascl1,
Brn2a and
Myt1l) are activated after transplantation using a drug.
Astrocytes – the most common
neuroglial brain cells, which contribute to
scar
formation in response to injury – can be directly reprogrammed in vivo
to become functional neurons that formed networks in mice without the
need of cell transplantation.
The researchers followed the mice for nearly a year to look for signs
of tumor formation and reported finding none. The same researchers have
turned scar-forming astrocytes into progenitor cells called neuroblasts
that regenerated into neurons in the injured adult spinal cord.
Oligodendrocyte precursor cells
Without
myelin
to insulate neurons, nerve signals quickly lose power. Diseases that
attack myelin, such as multiple sclerosis, result in nerve signals that
cannot propagate to nerve endings and as a consequence lead to
cognitive, motor and sensory problems. Transplantation of
oligodendrocyte
precursor cells (OPCs), which can successfully create myelin sheaths
around nerve cells, is a promising potential therapeutic response.
Direct lineage conversion of mouse and rat fibroblasts into
oligodendroglial cells provides a potential source of OPCs. Conversion
by forced expression of both eight or of the three transcription factors Sox10, Olig2 and Zfp536, may provide such cells.
Cardiomyocytes
Cell-based
in vivo therapies may provide a transformative approach to augment
vascular and muscle growth and to prevent non-contractile scar formation
by delivering transcription factors or microRNAs to the heart. Cardiac fibroblasts, which represent 50% of the cells in the mammalian heart, can be reprogrammed into
cardiomyocyte-like
cells in vivo by local delivery of cardiac core transcription factors (
GATA4, MEF2C, TBX5 and for improved reprogramming plus ESRRG, MESP1,
Myocardin and ZFPM2) after coronary
ligation.
These results implicated therapies that can directly remuscularize the
heart without cell transplantation. However, the efficiency of such
reprogramming turned out to be very low and the phenotype of received
cardiomyocyte-like cells does not resemble those of a mature normal
cardiomyocyte. Furthermore, transplantation of cardiac transcription
factors into injured murine hearts resulted in poor cell survival and
minimal expression of cardiac genes.
Meanwhile, advances in the methods of obtaining cardiac myocytes in vitro occurred.
Efficient cardiac differentiation of human iPS cells gave rise to
progenitors that were retained within infarcted rat hearts and reduced
remodeling of the heart after ischemic damage.
The team of scientists, who were led by Sheng Ding, used a
cocktail of nine chemicals (9C) for transdifferentiation of human skin
cells into beating heart cells. With this method, more than 97% of the
cells began beating, a characteristic of fully developed, healthy heart
cells. The chemically induced cardiomyocyte-like cells (ciCMs) uniformly
contracted and resembled human cardiomyocytes in their transcriptome,
epigenetic, and electrophysiological properties. When transplanted into
infarcted mouse hearts, 9C-treated fibroblasts were efficiently
converted to ciCMs and developed into healthy-looking heart muscle cells
within the organ.
This chemical reprogramming approach, after further optimization, may
offer an easy way to provide the cues that induce heart muscle to
regenerate locally.
In another study,
ischemic cardiomyopathy
in the murine infarction model was targeted by iPS cell
transplantation. It synchronized failing ventricles, offering a
regenerative strategy to achieve resynchronization and protection from
decompensation by dint of improved left ventricular conduction and contractility, reduced scarring and reversal of structural remodelling.
One protocol generated populations of up to 98% cardiomyocytes from hPSCs simply by modulating the canonical
Wnt signaling pathway at defined time points in during differentiation, using readily accessible small molecule compounds.
Discovery of the mechanisms controlling the formation of
cardiomyocytes led to the development of the drug ITD-1, which
effectively clears the cell surface from
TGF-β
receptor type II and selectively inhibits intracellular TGF-β
signaling. It thus selectively enhances the differentiation of
uncommitted
mesoderm to cardiomyocytes, but not to vascular smooth muscle and endothelial cells.
One project seeded decellularized mouse hearts with human
iPSC-derived multipotential cardiovascular progenitor cells. The
introduced cells migrated, proliferated and differentiated in situ into
cardiomyocytes, smooth muscle cells and endothelial cells to reconstruct
the hearts. In addition, the heart's extracellular matrix (the
substrate of heart scaffold) signalled the human cells into becoming the
specialised cells needed for proper heart function. After 20 days of
perfusion with growth factors, the engineered heart tissues started to
beat again and were responsive to drugs.
Reprogramming of cardiac fibroblasts into induced cardiomyocyte-like cells (iCMs)
in situ represents a promising strategy for cardiac regeneration. Mice exposed
in vivo, to three cardiac transcription factors GMT (Gata4, Mef2c, Tbx5) and the small-molecules:
SB-431542
(the transforming growth factor (TGF)-β inhibitor), and XAV939 (the WNT
inhibitor) for 2 weeks after myocardial infarction showed significantly
improved reprogramming (reprogramming efficiency increased eight-fold)
and cardiac function compared to those exposed to only GMT.
Rejuvenation of the muscle stem cell
The elderly often suffer from progressive
muscle weakness and regenerative failure owing in part to elevated activity of the
p38α and p38β mitogen-activated kinase
pathway in senescent skeletal muscle stem cells. Subjecting such stem
cells to transient inhibition of p38α and p38β in conjunction with
culture on soft
hydrogel substrates rapidly expands and rejuvenates them that result in the return of their strength.
In geriatric mice, resting satellite cells lose reversible
quiescence by switching to an irreversible pre-senescence state, caused
by derepression of
p16INK4a
(also called Cdkn2a).
On injury, these cells fail to activate and expand, even in a youthful
environment. p16INK4a silencing in geriatric satellite cells restores
quiescence and muscle regenerative functions.
Myogenic progenitors for potential use in disease modeling or
cell-based therapies targeting skeletal muscle could also be generated
directly from induced pluripotent stem cells using
free-floating spherical culture (EZ spheres) in a culture medium supplemented with high concentrations (100 ng/ml) of fibroblast growth factor-2 (
FGF-2) and
epidermal growth factor.
Hepatocytes
Unlike current protocols for deriving
hepatocytes from human fibroblasts, Saiyong Zhu et al., (2014)
did not generate iPSCs but, using small molecules, cut short
reprogramming to pluripotency to generate an induced multipotent
progenitor cell (iMPC) state from which endoderm progenitor cells and
subsequently hepatocytes (iMPC-Heps) were efficiently differentiated.
After transplantation into an immune-deficient mouse model of human
liver failure, iMPC-Heps proliferated extensively and acquired levels of
hepatocyte function similar to those of human primary adult
hepatocytes. iMPC-Heps did not form tumours, most probably because they
never entered a pluripotent state.
An intestinal crypt - an accessible and abundant source of intestinal epithelial cells for conversion into β-like cells.
These results establish the feasibility of significant liver
repopulation of mice with human hepatocytes generated in vitro, which
removes a long-standing roadblock on the path to autologous liver cell
therapy.
Cocktail of small molecules,
Y-27632, A-83-01 (a TGFβ kinase/activin receptor like kinase (
ALK5) inhibitor), and CHIR99021 (potent inhibitor of
GSK-3),
can convert rat and mouse mature hepatocytes in vitro into
proliferative bipotent cells – CLiPs (chemically induced liver
progenitors). CLiPs can differentiate into both mature hepatocytes and
biliary epithelial cells that can form functional ductal structures. In
long-term culture CLiPs did not lose their proliferative capacity and
their hepatic differentiation ability, and can repopulate chronically
injured liver tissue.
Insulin-producing cells
Complications of
Diabetes mellitus such as
cardiovascular diseases,
retinopathy,
neuropathy,
nephropathy and peripheral circulatory diseases depend on
sugar dysregulation due to lack of
insulin from pancreatic
beta cells
and can be lethal if they are not treated. One of the promising
approaches to understand and cure diabetes is to use pluripotent stem
cells (PSCs), including embryonic stem cells (ESCs) and induced PCSs
(iPSCs).
Unfortunately, human PSC-derived insulin-expressing cells resemble human
fetal β cells rather than adult β cells. In contrast to adult β cells,
fetal β cells seem functionally immature, as indicated by increased
basal glucose secretion and lack of glucose stimulation and confirmed by
RNA-seq of whose
transcripts.
An alternative strategy is the conversion of fibroblasts towards
distinct endodermal progenitor cell populations and, using cocktails of
signalling factors, successful differentiation of these endodermal
progenitor cells into functional beta-like cells both in vitro and in
vivo.
Overexpression of the three
transcription factors,
PDX1 (required for
pancreatic bud outgrowth and beta-cell maturation),
NGN3 (required for endocrine precursor cell formation) and
MAFA
(for beta-cell maturation) combination (called PNM) can lead to the
transformation of some cell types into a beta cell-like state.
An accessible and abundant source of functional insulin-producing cells is
intestine. PMN expression in human intestinal "
organoids" stimulates the conversion of intestinal epithelial cells into β-like cells possibly acceptable for
transplantation.
Nephron Progenitors
Adult proximal tubule cells were directly transcriptionally reprogrammed to
nephron progenitors of the embryonic
kidney,
using a pool of six genes of instructive transcription factors (SIX1,
SIX2, OSR1, Eyes absent homolog 1(EYA1), Homeobox A11 (HOXA11) and Snail
homolog 2 (SNAI2)) that activated genes consistent with a cap
mesenchyme/nephron progenitor phenotype in the adult proximal tubule
cell line.
The generation of such cells may lead to cellular therapies for adult
renal disease. Embryonic kidney organoids placed into adult rat kidneys can undergo onward development and vascular development.
Blood vessel cells
As
blood vessels age, they often become abnormal in structure and
function, thereby contributing to numerous age-associated diseases
including myocardial infarction, ischemic stroke and atherosclerosis of
arteries supplying the heart, brain and lower extremities. So, an
important goal is to stimulate vascular growth for the
collateral circulation
to prevent the exacerbation of these diseases. Induced Vascular
Progenitor Cells (iVPCs) are useful for cell-based therapy designed to
stimulate coronary collateral growth. They were generated by partially
reprogramming endothelial cells. The vascular commitment of iVPCs is related to the
epigenetic memory
of endothelial cells, which engenders them as cellular components of
growing blood vessels. That is why, when iVPCs were implanted into
myocardium,
they engrafted in blood vessels and increased coronary collateral flow
better than iPSCs, mesenchymal stem cells, or native endothelial cells.
Ex vivo genetic modification can be an effective strategy to
enhance stem cell function. For example, cellular therapy employing
genetic modification with
Pim-1 kinase (a downstream effector of
Akt, which positively regulates neovasculogenesis) of
bone marrow–derived cells or human cardiac progenitor cells, isolated from failing myocardium results in durability of repair, together with the improvement of functional parameters of myocardial hemodynamic performance.
Stem cells extracted from fat tissue after
liposuction may be coaxed into becoming progenitor
smooth muscle cells (iPVSMCs) found in arteries and veins.
The 2D culture system of human iPS cells in conjunction with triple marker selection (
CD34 (a surface glycophosphoprotein expressed on developmentally early embryonic fibroblasts),
NP1 (receptor – neuropilin 1) and
KDR
(kinase insert domain-containing receptor)) for the isolation of
vasculogenic precursor cells from human iPSC, generated endothelial
cells that, after transplantation, formed stable, functional mouse blood
vessels in vivo, lasting for 280 days.
To treat infarction, it is important to prevent the formation of
fibrotic scar tissue. This can be achieved in vivo by transient
application of
paracrine
factors that redirect native heart progenitor stem cell contributions
from scar tissue to cardiovascular tissue. For example, in a mouse
myocardial infarction model, a single intramyocardial injection of human
vascular endothelial growth factor A
mRNA (VEGF-A modRNA), modified to escape the body's normal defense
system, results in long-term improvement of heart function due to
mobilization and redirection of epicardial progenitor cells toward
cardiovascular cell types.
Blood stem cells
Red blood cells
RBC
transfusion
is necessary for many patients. However, to date the supply of RBCs
remains labile. In addition, transfusion risks infectious disease
transmission. A large supply of safe RBCs generated in vitro would help
to address this issue. Ex vivo erythroid cell generation may provide
alternative transfusion products to meet present and future clinical
requirements. Red blood cells (RBC)s generated in vitro from mobilized
CD34 positive cells have normal survival when transfused into an autologous recipient. RBC produced in vitro contained exclusively
fetal hemoglobin
(HbF), which rescues the functionality of these RBCs. In vivo the
switch of fetal to adult hemoglobin was observed after infusion of
nucleated
erythroid precursors derived from iPSCs.
Although RBCs do not have nuclei and therefore can not form a tumor,
their immediate erythroblasts precursors have nuclei. The terminal
maturation of erythroblasts into functional RBCs requires a complex
remodeling process that ends with extrusion of the nucleus and the
formation of an enucleated RBC.
Cell reprogramming often disrupts enucleation. Transfusion of in
vitro-generated RBCs or erythroblasts does not sufficiently protect
against tumor formation.
The
aryl
hydrocarbon receptor (AhR) pathway (which has been shown to be involved
in the promotion of cancer cell development) plays an important role in
normal blood cell development. AhR activation in human hematopoietic
progenitor cells (HPs) drives an unprecedented expansion of HPs,
megakaryocyte- and erythroid-lineage cells.
See also Concise Review:
The
SH2B3
gene encodes a negative regulator of cytokine signaling and naturally
occurring loss-of-function variants in this gene increase RBC counts in
vivo. Targeted suppression of SH2B3 in primary human hematopoietic stem
and progenitor cells enhanced the maturation and overall yield of
in-vitro-derived RBCs. Moreover, inactivation of SH2B3 by
CRISPR/
Cas9 genome editing in human pluripotent stem cells allowed enhanced erythroid cell expansion with preserved differentiation.
Platelets extruded from megakaryocytes
Platelets
Platelets help prevent hemorrhage in
thrombocytopenic patients and patients with
thrombocythemia.
A significant problem for multitransfused patients is refractoriness to
platelet transfusions. Thus, the ability to generate platelet products
ex vivo and platelet products lacking
HLA antigens in serum-free media would have clinical value.
An
RNA interference-based mechanism used a
lentiviral vector
to express short-hairpin RNAi targeting β2-microglobulin transcripts in
CD34-positive cells. Generated platelets demonstrated an 85% reduction
in class I HLA antigens. These platelets appeared to have normal
function in vitro.
One clinically-applicable strategy for the derivation of
functional platelets from human iPSC involves the establishment of
stable immortalized megakaryocyte progenitor cell lines (imMKCLs)
through
doxycycline-dependent overexpression of
BMI1 and
BCL-XL. The resulting imMKCLs can be expanded in culture over extended periods (4–5 months), even after
cryopreservation. Halting the overexpression (by the removal of doxycycline from the medium) of c-MYC,
BMI1 and
BCL-XL in growing imMKCLs led to the production of
CD42b+ platelets with functionality comparable to that of native platelets on the basis of a range of assays in vitro and in vivo.
Thomas et al., describe a forward programming strategy relying on the
concurrent exogenous expression of 3 transcription factors:
GATA1,
FLI1 and
TAL1. The forward programmed
megakaryocytes proliferate and differentiate in culture for several months with megakaryocyte purity over 90% reaching up to 2x10
5
mature megakaryocytes per input hPSC. Functional platelets are
generated throughout the culture allowing the prospective collection of
several transfusion units from as few as one million starting hPSCs.
Immune cells
A specialised type of
white blood cell, known as
cytotoxic T lymphocytes (CTLs), are produced by the
immune system
and are able to recognise specific markers on the surface of various
infectious or tumour cells, causing them to launch an attack to kill the
harmful cells. Thence, immunotherapy with functional antigen-specific T
cells has potential as a therapeutic strategy for combating many
cancers and viral infections. However, cell sources are limited, because they are produced in small numbers naturally and have a short lifespan.
A potentially efficient approach for generating antigen-specific
CTLs is to revert mature immune T cells into iPSCs, which possess
indefinite proliferative capacity in vitro and after their
multiplication to coax them to redifferentiate back into T cells.
Another method combines iPSC and
chimeric antigen receptor (CAR) technologies to generate human T cells targeted to
CD19, an antigen expressed by malignant
B cells, in tissue culture. This approach of generating therapeutic human T cells may be useful for cancer immunotherapy and other medical applications.
Invariant
natural killer T (iNKT) cells have great clinical potential as
adjuvants for cancer immunotherapy. iNKT cells act as innate T lymphocytes and serve as a bridge between the
innate and
acquired immune systems. They augment anti-tumor responses by producing
interferon-gamma (IFN-γ).
The approach of collection, reprogramming/dedifferentiation,
re-differentiation and injection has been proposed for related tumor
treatment.
Dendritic cells
(DC) are specialized to control T-cell responses. DC with appropriate
genetic modifications may survive long enough to stimulate
antigen-specific CTL and after that be completely eliminated. DC-like
antigen-presenting cells obtained from human induced pluripotent stem
cells can serve as a source for
vaccination therapy.
CCAAT/enhancer binding protein-α (C/EBPα) induces transdifferentiation of
B cells into
macrophages at high efficiencies and enhances reprogramming into iPS cells when co-expressed with transcription factors Oct4, Sox2, Klf4 and Myc. with a 100-fold increase in iPS cell reprogramming efficiency, involving 95% of the population.
Furthermore, C/EBPa can convert selected human B cell lymphoma and
leukemia cell lines into macrophage-like cells at high efficiencies,
impairing the cells' tumor-forming capacity.
Thymic epithelial cells rejuvenation
The
thymus
is the first organ to deteriorate as people age. This shrinking is one
of the main reasons the immune system becomes less effective with age.
Diminished expression of the
thymic epithelial cell transcription factor
FOXN1 has been implicated as a component of the mechanism regulating age-related involution.
Clare Blackburn
and colleagues show that established age-related thymic involution can
be reversed by forced upregulation of just one transcription factor –
FOXN1 in the thymic epithelial cells in order to promote
rejuvenation, proliferation and differentiation of these cells into fully functional thymic epithelium.
This rejuvenation and increased proliferation was accompanied by upregulation of genes that promote
cell cycle progression (
cyclin D1, ΔN
p63,
FgfR2IIIb) and that are required in the thymic epithelial cells to promote specific aspects of
T cell development (
Dll4,
Kitl,
Ccl25,
Cxcl12,
Cd40,
Cd80,
Ctsl,
Pax1).
Mesenchymal stem cells
Induction
mesenchymal stem/stromal cells
(MSCs) are under investigation for applications in cardiac, renal,
neural, joint and bone repair, as well as in inflammatory conditions and
hemopoietic cotransplantation.
This is because of their immunosuppressive properties and ability to
differentiate into a wide range of mesenchymal-lineage tissues. MSCs are
typically harvested from adult bone marrow or fat, but these require
painful invasive procedures and are low-frequency sources, making up
only 0.001–0.01% of bone marrow cells and 0.05% in liposuction
aspirates.
Of concern for autologous use, in particular in the elderly most in
need of tissue repair, MSCs decline in quantity and quality with age.
IPSCs could be obtained by the cells rejuvenation of even centenarians.
Because iPSCs can be harvested free of ethical constraints and culture
can be expanded indefinitely, they are an advantageous source of MSCs. IPSC treatment with
SB-431542 leads to rapid and uniform MSC generation from human iPSCs. (SB-431542 is an inhibitor of activin/TGF- pathways by blocking
phosphorylation of
ALK4,
ALK5 and
ALK7
receptors.) These iPS-MSCs may lack teratoma-forming ability, display a
normal stable karyotype in culture and exhibit growth and
differentiation characteristics that closely resemble those of primary
MSCs. It has potential for in vitro scale-up, enabling MSC-based
therapies.
MSC derived from iPSC have the capacity to aid periodontal regeneration
and are a promising source of readily accessible stem cells for use in
the clinical treatment of periodontitis.
Lai et al., & Lu report the chemical method to generate
MSC-like cells (iMSCs), from human primary dermal fibroblasts using six
chemical inhibitors (SP600125, SB202190, Go6983, Y-27632, PD0325901, and
CHIR99021) with or without 3 growth factors (transforming growth
factor-β (TGF-β), basic fibroblast growth factor (bFGF), and leukemia
inhibitory factor (LIF)). The chemical cocktail directly converts human
fibroblasts to iMSCs with a monolayer culture in 6 days, and the
conversion rate was approximately 38%.
Besides cell therapy in vivo, the culture of human mesenchymal stem cells can be used in vitro for mass-production of
exosomes, which are ideal vehicles for drug delivery.
Dedifferentiated adipocytes
Adipose
tissue, because of its abundance and relatively less invasive harvest
methods, represents a source of mesenchymal stem cells (MSCs).
Unfortunately, liposuction aspirates are only 0.05% MSCs.
However, a large amount of mature adipocytes, which in general have
lost their proliferative abilities and therefore are typically
discarded, can be easily isolated from the adipose cell suspension and
dedifferentiated into
lipid-free
fibroblast-like cells, named dedifferentiated fat (DFAT) cells. DFAT
cells re-establish active proliferation ability and express multipotent
capacities.
Compared with adult stem cells, DFAT cells show unique advantages in
abundance, isolation and homogeneity. Under proper induction culture in
vitro or proper environment in vivo, DFAT cells could demonstrate
adipogenic, osteogenic, chondrogenic and myogenic potentials. They could
also exhibit perivascular characteristics and elicit
neovascularization.
Chondrogenic cells
Cartilage
is the connective tissue responsible for frictionless joint movement.
Its degeneration ultimately results in complete loss of joint function
in the late stages of
osteoarthritis. As an avascular and hypocellular tissue, cartilage has a limited capacity for self-repair.
Chondrocytes are the only cell type in cartilage, in which they are surrounded by the extracellular matrix that they secrete and assemble.
One method of producing cartilage is to induce it from iPS cells.
Alternatively, it is possible to convert fibroblasts directly into
induced chondrogenic cells (iChon) without an intermediate iPS cell
stage, by inserting three reprogramming factors (c-MYC, KLF4 and SOX9). Human iChon cells expressed marker genes for chondrocytes (type II collagen) but not fibroblasts.
Implanted into defects created in the articular cartilage of
rats, human iChon cells survived to form cartilaginous tissue for at
least four weeks, with no tumors. The method makes use of c-MYC, which
is thought to have a major role in tumorigenesis and employs a
retrovirus to introduce the reprogramming factors, excluding it from unmodified use in human therapy.
Sources of cells for reprogramming
The most frequently used sources for reprogramming are blood cells and fibroblasts, obtained by biopsy of the skin, but taking cells from
urine is less invasive.
The latter method does not require a biopsy or blood sampling. As of
2013, urine-derived stem cells had been differentiated into endothelial,
osteogenic, chondrogenic, adipogenic, skeletal myogenic and neurogenic
lineages, without forming teratomas.
Therefore, their epigenetic memory is suited to reprogramming into iPS
cells. However, few cells appear in urine, only low conversion
efficiencies had been achieved and the risk of bacterial contamination
is relatively high.
Another promising source of cells for reprogramming are mesenchymal stem cells derived from human hair follicles.
The origin of somatic cells used for reprogramming may influence the efficiency of reprogramming, the functional properties of the resulting induced stem cells and the ability to form tumors.
IPSCs retain an epigenetic memory of their tissue of origin, which impacts their differentiation potential.
This epigenetic memory does not necessarily manifest itself at the
pluripotency stage – iPSCs derived from different tissues exhibit proper
morphology, express pluripotency markers and are able to differentiate
into the three embryonic layers in vitro and in vivo. However, this
epigenetic memory may manifest during re-differentiation into specific
cell types that require the specific loci bearing residual epigenetic
marks.
_gives_a_Fluoride_treatment_to_a_patient_during_a_Continuing_Promise_2009_medical_civil_service_projec.jpg)
